SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-18-013983
Filing Date
2018-11-08
Accepted
2018-11-08 16:04:22
Documents
8
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 6-K auph-0930186xk.htm 6-K 17961
2 EXHIBIT 99.1 exhibit991-interimconsolid.htm EX-99.1 852088
3 EXHIBIT 99.2 exhibit992-mda09302018.htm EX-99.2 311824
4 EXHIBIT 99.3 exhibit993-certificationof.htm EX-99.3 15989
5 EXHIBIT 99.4 exhibit994-certificationof.htm EX-99.4 15857
6 aurinialogoa03.jpg GRAPHIC 15156
7 q3financialstatementscover.jpg GRAPHIC 146251
8 q3mdacover.jpg GRAPHIC 147690
  Complete submission text file 0001628280-18-013983.txt   1634735
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36421 | Film No.: 181169640
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1